Thursday, November 26, 10:48 pm IST
Hot Searches:  mahindra satyamITCtata steel
| Feedback
Moneycontrol » News Center » Stocks » Brokerage Recommendations
Motilal Oswal neutral on Glenmark Pharma
Published on Tue, Sep 30, 2008 at 13:29   |  Updated at Tue, Sep 30, 2008 at 13:41  |  Source : Moneycontrol.com

Motilal Oswal has recommended a neutral rating on Glenmark Pharma with a target of Rs 635 in its September 23, 2008 research report. "We expect Glenmark to record 54% CAGR for adjusted earnings driven by significant ramp up in US and branded generic markets. Our estimates exclude upsides from NCE research. We believe that Glenmark deserves premium valuations given its differentiated business model and strong earnings growth."

"We value the company on a sum-of-the-parts basis by valuing the ex-NCE business at 17x FY10E earnings and DCF value of Rs 150 per share for the NCE business. Our SOTP-based target price for Glenmark is Rs 635, an upside of 8%. We initiate coverage with a Neutral rating," says Motilal Oswal's research report.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment......

More news from Recommendations
Important Links Today:  Leadership Wall    Chat Calendar    The 10 List   
WHAT OTHERS LIKE
  • Most Read
  • Most Viewed
24 Hours
7 Days
1 Month
NEWS FROM OUR PARTNERS
©Network 18, 2009. All Rights Reserved